BioSpace News Archive

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate at the Baird Global Healthcare Conference on Wednesday, September 13th at 2:35 p.m. Eastern Time.

Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today received authorization of its Clinical Trial Application (CTA) by the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2 trial in Early Alzheimer’s disease (AD) with XPro™.

Foghorn ® Therapeutics Inc. today announced management’s participation in the following investor conferences in September 2023.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced its participation in the upcoming H.C. Wainwright 25th Annual Global Investment Conference.

Portage Biotech Inc. today announced that it has entered into a clinical trial collaboration agreement with Merck to evaluate Portage’s next-generation adenosine antagonists in combination with KEYTRUDA ® (pembrolizumab).

pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine / indapamide) is used in adults for the initial treatment of mild to moderate essential hypertension (high blood pressure).

I-Mab today announced its participation in the following conferences in September 2023. Details of the conferences and management presentation are as follows.

Regulus Therapeutics Inc today announced that the Company will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference.

Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced the appointment of David Topper as Chief Financial Officer (CFO).